NASDAQ : YARW
Yarrow Bioscience, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 20 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 186.09M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | |
|---|---|---|
| Selling, General & Admin | 1.56M | 1.56M |
| Research & Development | 2.42M | 2.42M |
| Operating Expenses | 3.98M | 3.98M |
| Operating Income | -3.98M | -3.98M |
| EBT Excluding Unusual Items | -3.98M | -3.98M |
| Pretax Income | -283.98M | -283.98M |
| Net Income | -283.98M | -283.98M |
| Net Income to Common | -283.98M | -283.98M |
| Shares Outstanding (Basic) | 4.25M | 4.25M |
| Shares Outstanding (Diluted) | 4.25M | 4.25M |
| EPS (Basic) | -66.82 | -66.82 |
| EPS (Diluted) | -66.82 | -66.82 |
| EBIT | -3.98M | -3.98M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | |
|---|---|---|
| Cash & Equivalents | 99.99M | 99.99M |
| Cash & Short-Term Investments | 99.99M | 99.99M |
| Prepaid Expenses | 6.00K | 6.00K |
| Total Current Assets | 100.00M | 100.00M |
| Long-Term Deferred Charges | 407.00K | 407.00K |
| Total Assets | 100.41M | 100.41M |
| Accounts Payable | 1.53M | 1.53M |
| Accrued Expenses | 70.01M | 70.01M |
| Total Current Liabilities | 71.55M | 71.55M |
| Total Liabilities | 71.55M | 71.55M |
| Additional Paid-In Capital | 4.00K | 4.00K |
| Retained Earnings | -70.99M | -70.99M |
| Total Common Equity | -70.99M | -70.99M |
| Shareholders' Equity | 28.86M | 28.86M |
| Total Liabilities & Equity | 100.41M | 100.41M |
| Net Cash (Debt) | 99.99M | 99.99M |
| Net Cash Per Share | 23.53 | 23.53 |
| Filing Date Shares Outstanding | 4.25M | 4.25M |
| Total Common Shares Outstanding | 4.25M | 4.25M |
| Working Capital | 28.45M | 28.45M |
| Book Value Per Share | -16.70 | -16.70 |
| Tangible Book Value | -70.99M | -70.99M |
| Tangible Book Value Per Share | -16.70 | -16.70 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | |
|---|---|---|
| Net Income | -283.98M | -283.98M |
| Change in Accounts Payable | 4.51M | 4.51M |
| Change in Other Net Operating Assets | 280.03M | 280.03M |
| Operating Cash Flow | 560.00K | 560.00K |
| Issuance of Common Stock | 16.00K | 16.00K |
| Other Financing Activities | -600.00K | -600.00K |
| Financing Cash Flow | 399.42M | 399.42M |
| Net Cash Flow | 399.98M | 399.98M |
| Change in Working Capital | 284.54M | 284.54M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | |
|---|---|---|
| Last Close Price | 19.90 | 16.36 |
| Net Debt / Equity Ratio | -3.46 | -3.46 |
| Quick Ratio | 1.40 | 1.40 |
| Current Ratio | 1.40 | 1.40 |
| Return on Capital Employed (ROCE) | -13.80% | -13.80% |